The drug could begin clinical trials with patients in early 2022, with support from INER.
Expand your business,
Not your inbox
Stay informed and subscribe to our daily newsletter now!
Read for 2 minutes
This article was translated from our Spanish edition using AI technologies. Errors can occur because of this process.
This morning we want to sing the iconic jubilation of the National Polytechnic Institute (IPN): "Huélum, Huélum, Gloria A la Cachi Cachi Porra A la Cachi Cachi Porra Pim Pom Porra Pim Pom Porra Politécnico, Politécnico, Gloria!"
This is because a drug against COVID-19 developed by National School of Biological Sciences' virology and immunology expert Paola Castillo Juárez has shown greater than 90% effectiveness in treating the virus.
According to the IPN page, the treatment was created from the design of four peptides (small protein fragments). These inhibit the replication of the virus and stop the inflammation it creates, which is related to the multisystem damage that COVID-19 creates.
Image: Courtesy of IPN
"The results are surprising because the developed molecules concentrate on conserved sequences of the parts of the SARS-CoV-2 protein that do not change even when the virus is mutated and new variants arise," said the researcher in a statement from Pol .
Castillo Juarez said it is already in the process of filing a patent for the drug and that it will begin testing to verify its effectiveness against the Delta variant.
"Since the peptides are directed against sequences of the proteins of the virus that do not change (conserved), we are absolutely certain that they will also be very effective against this variant," said the scientist.
The drug now has to be tested on animals by the end of 2021 in order to start the clinical trial with patients in early 2022 with the support of the National Institute of Respiratory Diseases (INER).